Canaccord analyst Mark Massaro says shares of T2 Biosystems are under pressure on a short report that appears on Seeking Alpha. While the report says that breakthrough Device designation by the FDA is not an acknowledgement of the device's effectiveness or clinical value proposition, or that the device has value, only that it diagnoses life-threatening disease, the analyst still sees the designation as a positive. The analyst also does not agree with the short report's arguments that the company's small device sales number are worse than they seem, the T2MR bacterial test does not replace blood cultures and that many other similar bloodstream test devices have gone bust. While the author of the report expects the company to lower 2019 guidance, Massaro does not believe he "substantiates his view in this report." The analyst reiterates a Buy rating and a $10 price target on the shares, and recommends buying the stock on weakness.